Form 8-K
8-K — BAXTER INTERNATIONAL INC
Accession: 0001193125-26-356188
Filed: 2026-08-19
Period: 2026-08-18
CIK: 0000010456
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — d154782d8k.htm (Primary)
EX-10.1 (d154782dex101.htm)
EX-99.1 (d154782dex991.htm)
GRAPHIC (g154782dsp007c.jpg)
GRAPHIC (g154782dsp007e.jpg)
GRAPHIC (g154782g0818051845275.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d154782d8k.htm · Sequence: 1
8-K
BAXTER INTERNATIONAL INC false 0000010456 0000010456 2026-08-18 2026-08-18 0000010456 bax:CommonStock1.00PerValueMember 2026-08-18 2026-08-18 0000010456 bax:GlobalNotes13Due2029Member 2026-08-18 2026-08-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 18, 2026
Baxter International Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-4448
36-0781620
(Commission
File Number)
(I.R.S. Employer
Identification No.)
One Baxter Parkway, Deerfield, Illinois
60015
(Address of principal executive offices)
(Zip Code)
(224) 948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $1.00 par value
BAX (NYSE)
New York Stock Exchange
1.3% Global Notes due 2029
BAX 29
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
☐
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of John Rogers as CFO
On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer (“CFO”), effective as of October 1, 2026 (the “Transition Date”).
Mr. Rogers, 58, is joining the Company from Smith+Nephew plc, where he has served as CFO since 2024 after beginning with the company as CFO-designate in 2023. Before Smith+Nephew, he served as CFO of WPP plc from 2020 to 2023. Rogers previously held leadership roles with J Sainsbury plc, including as CEO of Sainsbury’s Argos from 2016 to 2019 and as CFO of Sainsbury’s from 2010 to 2016. Mr. Rogers has also served as an independent director and audit committee chair of Grab Holdings Limited since 2021 and of Travis Perkins plc between 2014 and 2021. Mr. Rogers holds a master’s degree in electrical engineering from Imperial College London and an MBA from INSEAD, and has completed the Advanced Management Program at Harvard Business School.
Mr. Rogers does not have any family relationships with any of the Company’s directors or executive officers, there are no arrangements or understandings between Mr. Rogers and any other persons pursuant to which he was selected as an officer, and there are no transactions between Mr. Rogers and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
The Company and Mr. Rogers entered into an offer letter (the “Offer Letter”), dated August 18, 2026, establishing the terms of Mr. Roger’s services as CFO. Mr. Rogers’s target direct compensation will comprise an annual base salary of $925,000, a target annual bonus opportunity under the Company’s Management Incentive Compensation Program of 100% of his annual base salary (including eligibility for a prorated bonus opportunity for 2026 based on the number of days worked in 2026), and participation in the Company’s annual equity program (beginning with the 2027 annual equity grant) with a target annual equity grant value of $4,000,000 (the “LTI Target Value”). He will be eligible to participate in the Company’s Executive Severance and Change in Control Plan.
Mr. Rogers is also eligible to receive two off-cycle equity grants pursuant to the Company’s Second Amended and Restated 2021 Incentive Plan (the “Plan”) as compensation for the unvested portion of certain equity awards previously granted by Mr. Rogers’ prior employer, which will be granted on the first quarterly off cycle grant date on or after the Transition Date, comprising: (i) an award with a target grant value equal to the LTI Target Value, prorated for the number of days worked in 2026, consisting of 50% performance-based restricted stock units, 25% restricted stock units and 25% stock options and (ii) a target grant value of $3,861,494, consisting of 50% performance-based restricted stock units and 50% restricted stock units. The restricted stock units and stock options will vest one-third per year on the first three anniversaries of the grant date and the performance period against which the performance-based restricted stock units will be measured will be January 1, 2026 through December 21, 2028 using the metric and targets set for that performance period for all other eligible participants under the Company’s long-term incentive program. In addition, Mr. Rogers will receive a sign-on bonus of $2,827,629, to replace certain incentive compensation to which he would have been entitled at his prior employer had he remained, which amount he will be required to repay in full if his employment with the Company is terminated for any reason by him or by the Company (except through death, permanent disability or a qualifying termination for which he is eligible for severance under the Company’s Executive Severance and Change in Control Plan) within 12 months of his start date, or 50% upon the same occurring within 12 to 24 months of his start date.
The above description of the Offer Letter is qualified in its entirety by reference to the terms of the Offer Letter, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Appointment of Andrew Hider as Interim CFO
As previously announced, Anita Zielinski, the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, will depart the Company, effective as of September 15, 2026. The Company has appointed Andrew Hider, the Company’s President and Chief Executive Officer, to serve as interim CFO of the Company during the anticipated two-week interim period from September 15, 2026 until the Transition Date. Mr. Hider will also continue to serve in his current role and retain his responsibilities as President and Chief Executive Officer, which responsibilities will continue past the Transition Date.
Mr. Hider does not have any family relationships with any of the Company’s directors or executive officers, there are no arrangements or understandings between Mr. Hider and any other persons pursuant to which he was selected as an officer, and there are no transactions between Mr. Hider and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
Mr. Hider will not be receiving any additional compensation in connection with his service as interim CFO.
Appointment of Bernie Heine as Interim CAO and Controller
In addition, the Company appointed Bernie Heine, the Company’s Assistant Controller, as Associate Vice President, Finance, interim Chief Accounting Officer (“CAO”) and Controller of the Company effective September 15, 2026 while the Company undertakes an executive search process for a permanent CAO. Mr. Heine will also continue to serve in his current role and retain his responsibilities as Assistant Controller during this search.
Mr. Heine, 40, joined the Company in 2023 as Senior Director, Finance – Assistant Controller. Before joining the Company, he worked for PricewaterhouseCoopers LLP for 15 years, most recently, beginning in 2018, as an Assurance Director. Mr. Heine holds an integrated bachelor’s degree and master’s degree in professional accountancy from Illinois State University.
Mr. Heine does not have any family relationships with any of the Company’s directors or executive officers, there are no arrangements or understandings between Mr. Heine and any other persons pursuant to which he was selected as an officer, and there are no transactions between Mr. Heine and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
In connection with Mr. Heine’s appointment, the Company entered into amended compensation arrangements with Mr. Heine providing the following additional compensation effective as of his appointment date and for so long as Mr. Heine serves as interim CAO and Controller: a payment of $15,000 per month for each month Mr. Heine serves in this capacity, and a one-time special award of restricted stock units pursuant to the Plan, with a grant date value equal to $250,000, which will be granted on September 1, 2026 and which will be scheduled to vest on the third anniversary of the grant date.
Item 7.01
Regulation FD Disclosure
On August 19, 2026, the Company issued a press release announcing, among other things, the appointment of Mr. Rogers as the Company’s CFO. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except in the event that the Company expressly states that such information is to be considered filed under the Exchange Act or incorporates it by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
10.1
Offer Letter, effective as of August 18, 2026, by and between John Rogers and the Company
99.1
Press Release Dated August 19, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BAXTER INTERNATIONAL INC.
Date: August 19, 2026
By:
/s/ Ellen K. Bradford
Name:
Ellen K. Bradford
Title:
Senior Vice President and Corporate Secretary
EX-10.1
EX-10.1
Filename: d154782dex101.htm · Sequence: 2
EX-10.1
Exhibit 10.1
August 18, 2026
Mr. John Rogers
Dear John,
We are pleased to welcome you to Baxter International Inc. (“Baxter” or the “Company”) and to confirm our verbal offer of employment,
subject to formal approval by the Board of Directors of Baxter (the “Board”). This is where your purpose accelerates our mission to Save and Sustain Lives. At Baxter, you will join approximately 38,000 colleagues, in 100 countries, who
share common traits like being reliable, ethical, and caring. Together, we create a place where we are happy, successful and inspire each other.
Your
first day of employment is anticipated to be October 1, 2026, but is contingent upon you seeking the proper visa and/or work permits to enable you to legally work in the United States for Baxter. Your job title will be Executive Vice President,
Chief Financial Officer reporting to Andrew Hider, President and Chief Executive Officer. Upon your confirming your intention to accept this agreement, we will seek formal approval from the Board, which we anticipate will formally appoint you as an
executive officer of the Company effective on your first day of employment.
This role, which is a full-time exempt position, is based in Deerfield,
Illinois and is not remote. It is a condition of your employment at Baxter that you remain eligible for and seek authorization to work in the United States. Baxter’s immigration advisors will provide reasonable assistance and support your
obtaining the relevant visa that will allow you to work in the United States. Upon your obtaining the relevant authorization to work in the United States, you will relocate to Deerfield, Illinois (and will receive relocation assistance as described
below). If you have not obtained authorization to work in the United States prior to your first day of employment, you shall perform your duties as CFO from Baxter’s offices in the United Kingdom pending the relevant visa and authorization to
work in the United States.
TERMS OF EMPLOYMENT
The
following explains the terms of your employment. Please note that all compensation actions are subject to approval by the Compensation and Human Capital Committee (“CHCC”) of the Board.
•
Your salary will be $925,000 annualized, less applicable deductions and withholdings.
•
You will be eligible to participate in the Management Incentive Compensation Program (the “Program”)
with a bonus target of 100% of your annual salary. For 2026, you will be eligible for a prorated bonus opportunity based on the number of days worked in 2026. The actual bonus you will receive will vary depending on both Baxter performance and your
individual assessment for the year, and the bonus is subject to the other terms and conditions of the Program.
•
You will be eligible to participate in the Company’s annual equity program. The next annual equity grant is
scheduled for March of 2027, assuming your start date is on or prior to the grant date. Your target annual equity grant value will be $4,000,000. We anticipate that your annual equity grant will be a mix of 50% performance share units (PSUs), 25%
restricted stock units (RSUs) and 25% stock options, or such other mix as shall then be provided to other senior executives under Baxter’s Long-Term Incentive Plan . Your target grant value will be converted into the applicable number of PSUs,
RSUs and stock options using the company’s standard calculation methodology. The Company’s equity targets and mix are assessed annually and are subject to change based on market competitiveness and the Company’s financial
performance. Your actual equity target grant value will be based on a combination of your equity target and an assessment of your individual performance and potential. All equity grants are subject to the terms and conditions of the underlying
equity plan and corresponding agreements, including the Agreement Regarding Competition and Protection of Proprietary Interests (the “CPPI Agreement”).
•
You will receive two off-cycle equity grants:
•
The first has a target grant value equal to the target annual grant prorated based on your start date, which will
be delivered 50% in PSUs, 25% in RSUs, and 25% in stock options
•
The second has a target grant value of $3,861,494, which will be delivered 50% in PSUs and 50% RSUs.
Both grants will be made during the first quarterly off-cycle grant date after
your date of hire (customarily the first business day of March, June, September or December). All RSUs and stock options will vest one-third per year on the first three anniversaries of the grant date, so long
as you remain employed with the Company through the vesting dates. The performance period against which the PSUs will be measured will be January 1, 2026 through December 31, 2028, using the metrics and targets set for that performance
period for all other eligible participants, and are expected to vest following CHCC certification of the results in the first quarter of 2029. Both grants will be subject to the Clawback Policy.
•
In addition, you will receive a one-time, supplemental cash payment of
$2,827,629 minus applicable taxes. You will receive this supplemental cash payment after ninety (90) days of employment with Baxter, provided you are actively employed on the date of payment. This supplemental payment will not be considered
eligible earnings for Baxter’s qualified retirement or welfare benefit plans. Should your employment with the Company be terminated for any reason by you or by Baxter (except through death, permanent disability, or a Qualifying Termination for
which you are eligible for severance under Baxter’s Executive Severance and Change in Control Plan) within twelve (12) months of your start date, you will be responsible for 100% re-payment of this
bonus, and if within 12-24 months you will be responsible for 50% re-payment of this bonus. In addition, this payment will be subject to the Clawback Policy.
•
As a senior executive, your compensation increases are approved by the CHCC through a “pay for
performance” philosophy.
•
You will be eligible for an Annual PTO Allowance of 30 days subject to Baxter’s Paid Time Off (PTO) Policy.
Should your employment terminate, you will be paid for any earned and unused paid time off in accordance with Baxter’s standard policy.
•
During your employment with the Company, you may choose to serve on the board of directors of one for-profit company, provided, however, that the Company CEO must approve your participation on such board as not conflicting or interfering with your duties as CFO of the Company. It is acknowledged and agreed that
you may continue to serve on the board of directors of Grab Holdings Limited.
•
You will be covered by the Company’s Indemnification Agreement, and its Directors and Officers (D&O)
insurance, on the same terms and conditions as other senior executive officers.
•
The term of your employment is “at will”, which means that you or the Company may end your employment
at any time and for any reason.
STOCK OWNERSHIP GUIDELINES
•
You will be required to attain and hold Company stock equal in value to four (4) times your annual base
salary. Under current guidelines, you will have five years from your date of hire to achieve this level of ownership. Stock held for ownership determination includes common stock held directly or indirectly and unvested RSUs. It does not include
stock options or unvested PSUs. The Company reserves the right to change the guidelines at any time.
BENEFITS
•
Baxter provides a comprehensive benefits program. More detailed information regarding Baxter’s benefits
program will be discussed in New Employee Orientation. If you have immediate questions about benefits and coverage, you may contact Martha Peterson, Vice President Total Rewards, at
224-453-2353 (cell).
•
As of your start date, you will be eligible to participate in Baxter’s Flexible Benefits Program which
includes: Medical Benefits, Dental Benefits, Prescription Service, and Personal Accident Insurance, subject to the Plan’s provisions. Please note that you must enroll within 21 days of your start date to receive this coverage. You are also
immediately eligible for Basic Employee Term Life Insurance, Long Term Disability Insurance, and Business Travel Insurance. You will be eligible to contribute to the 401(k) plan immediately upon hire. At that time, you will also be eligible to
participate in the company’s matching in the plan. All Company benefits are subject to amendment, modification, and cancellation from time to time and are subject to the governing plan documents.
•
You will be eligible for reimbursement for an annual executive physical examination. The Company has a preferred
vendor relationship with Northwestern Executive Health. Information about the program is available upon request.
•
You will be eligible to participate in the U.S. Deferred Compensation Plan. Through this plan, you can elect to
defer eligible compensation (base salary and Management Incentive Compensation Plan bonus) and receive Company contributions in respect to amounts above the Internal Revenue Service limits set for qualified 401(k) plans.
•
You will be eligible to participate in the Employee Stock Purchase Program (the “ESPP”). However, as
a designated company insider, your participation in the ESPP will be contingent on receiving the appropriate pre-clearance to participate. Your subscription will begin on the first day of the calendar quarter (January 1, April 1, July 1 or October
1) following your enrollment. However, the deadline for entering your subscription is the 15th day of the month prior to the beginning of each calendar quarter (December 15, March 15, June 15 or September 15). If the first day of your subscription
period is not a trading day, then the next preceding trading day will be used. Please also note that these dates are subject to change and additional blackout periods may arise in accordance with the terms of Baxter’s Securities Trading
Policy.
•
You are eligible for the Baxter International Inc. Executive Severance and Change in Control Plan, which provides
certain benefits if you are involuntarily separated from the Company under qualifying circumstances. A copy of the Baxter International Inc. Executive Severance and Change in Control Plan is available upon request.
•
Baxter will reimburse you for United Kingdom and U.S. tax preparation services for the 2026 and 2027 tax years as
well as a tax consultation through the tax preparation firm of your choice. You are responsible for understanding your tax obligations in both countries. You should understand how your personal investments, property, other income, etc. may be
impacted by this transfer. In addition, due to varying global tax laws, it is important you understand the timing of when taxes will be due, as it does not always correspond with the calendar year, as well as understand your tax residency status and
implications, in both origin and destination country. While Baxter does provide tax gross up support on relocation expenses, the employee is responsible for all other tax obligations and payments as it relates to the transfer.
•
The Company will reimburse you (or pay directly), in an amount not to exceed $30,000, for reasonable, documented
attorneys’ fees incurred by you in connection with negotiating this offer.
•
You will be eligible for relocation benefits in accordance with our executive relocation program. Benefits
provided under this program are subject to the relocation repayment agreement. For the avoidance of doubt, you will not be required to repay any amount of relocation payments provided under the executive relocation program in the event of death,
permanent disability, or a Qualifying Termination for which you are eligible for severance under Baxter’s Executive Severance and Change in Control Plan.
Please note that Baxter’s Benefits are subject to change and any such change would supersede this letter, provided, that no such changes shall treat you
less favorably than other senior executives generally.
CONDITIONS OF EMPLOYMENT
•
Background Screen: Your employment is contingent upon confirmation that there have been no changes since
the successful completion of a background screen that was conducted by Mintz on behalf of Baxter.
•
Reference Verification: Your employment is contingent upon successful completion of and verification by
your personal references you provide to Baxter.
•
This letter also confirms that you have no obligations, oral or in writing, with any of your former employers
which restrict your ability to be employed by Baxter. You understand that your continued employment is contingent upon this representation. Additionally, Baxter has not made this offer of employment to you in order to obtain from you any
confidential or trade secret information of your former employers, and Baxter will not ask you to use or disclose such confidential and trade secret information in your Baxter employment. Indeed, you have a continuing obligation not to use or
disclose the confidential and trade secret information of your former employers, and, by entering into Baxter employment, you acknowledge that you will not use or disclose any of the confidential and trade secret information of your former
employers.
•
Drug Screening: Your employment is contingent upon your timely scheduling and completion of a drug
screening test in accordance with Company policy and receiving a negative result. If you have not already indicated your consent, you will be asked to do so before the screening is done. Please complete your drug screen within 72 hours of receiving
notification to do so.
•
Authorization to Work: Upon your obtaining the relevant visa and authorization to work in the United
States, federal guidelines require all new employees to complete I-9 forms within 72 hours of their start dates in the United States. You will receive an email with instructions on how to electronically complete the Employee Section, or Section 1
prior and a link to the acceptable forms of identification that you must bring on your first day of work in the United States. They will be used by your Human Resources representative to complete Section 2 of the I-9 form.
•
Employment Agreement: You have accepted a position of trust, which requires the maintenance of confidence.
Therefore, you are required to sign the Company Employment Agreement as part of your job tasks prior to start date. The benefits set forth in this offer letter, including the annual bonus opportunities, supplemental cash bonus, equity grants, and
participation in the Executive Severance Plan are contingent upon your execution of the Employment Agreement.
•
Baxter Code of Conduct and Executive Compensation Recoupment Policy: You will be emailed about our Code of
Conduct that communicates Baxter’s business ethics policies and procedures. Please read it as soon as practicable. You will be asked to acknowledge your receipt and understanding of Baxter’s Code of Conduct following your start date. You
and all applicable compensation will be subject to the Executive Compensation Recoupment Policy as in effect from time to time.
•
Entire Agreement and Modifications: Together with the Employment Agreement and other agreements referenced
herein, this offer letter includes the entire agreement between the parties on the subject matter hereof, and supersedes and replaces any prior offer or promise. Any subsequent modifications to this offer letter must be in writing and signed by a
duly authorized representative of the Company and by you.
John, we are confident that you will make a significant contribution to the
Company. Please indicate your acceptance by signing the offer and returning it to me. Please do not hesitate to contact me if you need any assistance or have any questions.
Sincerely,
/s/ Andrew Hider
Andrew Hider
President and Chief Executive Officer
AGREED TO AND ACCEPTED BY:
/s/ John Rogers
August 18, 2026
Name
Date
Enclosures: Employment Agreement
EX-99.1
EX-99.1
Filename: d154782dex991.htm · Sequence: 3
EX-99.1
Exhibit 99.1
FOR IMMEDIATE RELEASE
BAXTER APPOINTS JOHN ROGERS CHIEF FINANCIAL OFFICER
Global medtech CFO with broad transformation and leadership experience to help
advance Baxter’s turnaround, financial discipline and value creation
DEERFIELD, Ill., AUGUST 19, 2026 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as
executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026.
“John is a proven global finance executive with extensive operational expertise and a successful track record leading complex
transformation initiatives,” said Hider. “He is an ideal fit for Baxter as we continue to stabilize the business, strengthen our balance sheet and drive a culture of continuous improvement. I am confident John will help us build on this
work, sharpen our execution and create sustainable value for our customers, employees, investors and other Baxter stakeholders.”
Rogers joins Baxter from Smith+Nephew plc, a portfolio medical technology business, where he has served as CFO since 2024 after beginning with
the company as CFO-designate in 2023. Before Smith+Nephew, he served as CFO of WPP plc, a creative services company, where he led the company’s global transformation program. Rogers previously held
leadership roles with J Sainsbury plc, one of the UK’s leading food, general merchandise and clothing retailers, including as CEO of Sainsbury’s Argos, where he led a major digital transformation of its omnichannel business, and as CFO
of Sainsbury’s. Rogers also brings public-company board experience, including as an independent director and audit committee chair of Grab Holdings Limited and previously of Travis Perkins plc. He earned a master’s degree in electrical
engineering from Imperial College London, holds an MBA from INSEAD and completed the Advanced Management Program at Harvard Business School.
1
“I am honored to join Baxter, a company with a nearly century-long history, a powerful
Mission to Save and Sustain Lives and an essential role across healthcare,” said Rogers. “Baxter’s focus on continuous improvement, strengthening its balance sheet and driving enhanced performance is closely aligned with my
experience leading global finance organizations and supporting large-scale business transformation. I look forward to working with Andrew, the Finance team and my new colleagues across Baxter to create long-term value for all stakeholders.”
2026 Outlook
Baxter also announced
that it is reiterating its full-year 2026 financial outlook provided in its most recent earnings announcement on July 30, 2026.
About Baxter
At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital,
physician’s office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected
solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today,
tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release
contains forward-looking statements concerning the company’s outlook for full-year 2026 and ones that may predict, forecast, indicate or imply certain events or achievements such as statements in this press release related to Baxter’s
strategy, turnaround, ongoing transformation efforts, leadership transition and anticipated value creation. These forward-looking statements are based on assumptions about many important factors which could cause actual results to differ materially
from those in the forward-looking statements, including risks discussed in Baxter’s most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of
which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.
2
Media Contact
Stacey Eisen, (224) 948-5353
media@baxter.com
Investor Contact
Kevin Moran, (224) 948-3085
global_corp_investor_relations@baxter.com
###
3
GRAPHIC
GRAPHIC
Filename: g154782dsp007c.jpg · Sequence: 8
Binary file (14730 bytes)
Download g154782dsp007c.jpg
GRAPHIC
GRAPHIC
Filename: g154782dsp007e.jpg · Sequence: 9
Binary file (33080 bytes)
Download g154782dsp007e.jpg
GRAPHIC
GRAPHIC
Filename: g154782g0818051845275.jpg · Sequence: 10
Binary file (3542 bytes)
Download g154782g0818051845275.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 12
v3.26.1
Document and Entity Information
Aug. 18, 2026
Document And Entity Information [Line Items]
Entity Registrant Name
BAXTER INTERNATIONAL INC
Amendment Flag
false
Entity Central Index Key
0000010456
Document Type
8-K
Document Period End Date
Aug. 18, 2026
Entity Incorporation State Country Code
DE
Entity File Number
1-4448
Entity Tax Identification Number
36-0781620
Entity Address, Address Line One
One Baxter Parkway
Entity Address, City or Town
Deerfield
Entity Address, State or Province
IL
Entity Address, Postal Zip Code
60015
City Area Code
(224)
Local Phone Number
948-2000
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Common Stock 1.00 Per Value [Member]
Document And Entity Information [Line Items]
Security 12b Title
Common Stock, $1.00 par value
Trading Symbol
BAX (NYSE)
Security Exchange Name
NYSE
Global Notes 13 Due 2029 [Member]
Document And Entity Information [Line Items]
Security 12b Title
1.3% Global Notes due 2029
Trading Symbol
BAX 29
Security Exchange Name
NYSE
X
- References
No definition available.
+ Details
Name:
bax_DocumentAndEntityInformationLineItems
Namespace Prefix:
bax_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=bax_CommonStock1.00PerValueMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=bax_GlobalNotes13Due2029Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: